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mTORC1 Promotes T-bet Phosphorylation To Regulate
Th1 Differentiation
Olesya Chornoguz,*,†,‡,x Robert S. Hagan,*,†,‡,{ Azeb Haile,*,†,‡ Matthew L. Arwood,*,†,‡
Christopher J. Gamper,*,†,‡ Arnob Banerjee,‖,# and Jonathan D. Powell*,†,‡
CD4+ T cells lacking the mTORC1 activator Rheb fail to secrete IFN-g under Th1 polarizing conditions. We hypothesized that
this phenotype is due to defects in regulation of the canonical Th1 transcription factor T-bet at the level of protein phosphorylation
downstream of mTORC1. To test this hypothesis, we employed targeted mass-spectrometry proteomic analysis–multiple reaction
monitoring mass spectrometry. We used this method to detect and quantify predicted phosphopeptides derived from T-bet. By
analyzing activated murine wild-type and Rheb-deficient CD4+ T cells, as well as murine CD4+ T cells activated in the presence of
rapamycin, a pharmacologic inhibitor of mTORC1, we were able to identify six T-bet phosphorylation sites. Five of these are
novel, and four sites are consistently dephosphorylated in both Rheb-deficient CD4+ T cells and T cells treated with rapamycin,
suggesting mTORC1 signaling controls their phosphorylation. Alanine mutagenesis of each of the six phosphorylation sites was
tested for the ability to impair IFN-g expression. Single phosphorylation site mutants still support induction of IFN-g expression;
however, simultaneous mutation of three of the mTORC1-dependent sites results in significantly reduced IFN-g expression. The
reduced activity of the triple mutant T-bet is associated with its failure to recruit chromatin remodeling complexes to the Ifng gene
promoter. These results establish a novel mechanism by which mTORC1 regulates Th1 differentiation, through control of T-bet
phosphorylation. The Journal of Immunology, 2017, 198: 3939–3948.
T
he CD4+ T helper lymphocytes modulate immune re-
sponse to intracellular and extracellular pathogens,
provide help to B cells, and play an important role
in immune response to tumors. Upon activation, CD4+ T
helper lymphocytes differentiate into effector T cells (Th1,
Th2, Th17, T follicular helper, and T regulatory cells) with
restricted patterns of cytokine expression and functional
specificity (1). These subsets have unique roles during specific
classes of adaptive immune responses and each is characterized
by expression of critical lineage-determining transcription
factors such as T-bet, GATA3, RORgT, Foxp3, and Bcl-6 for
Th1, Th2, Th17, T regulatory, and T follicular helper cells,
respectively. Among important signals directing Th cell dif-
ferentiation are the cytokines present in the milieu during Th
cell activation. Many cytokines direct CD4+ T cell differenti-
ation by binding to their cognate receptors and activating STAT
family transcription factors (2). When a naive CD4+ T cell is
activated in the presence of IL-12 and IFN-g and in the absence
of IL-4, it becomes a Th1 cell. During the initial phase of
differentiation, TCR and IFN-g–induced STAT1-signaling
pathways synergize to induce T-bet expression, a T-box fam-
ily transcription factor that is critical for Th1 differentiation
(3). In the later stages of differentiation, IL-12–induced STAT4
signaling sustains T-bet expression in the absence of TCR
stimulation (4). Although molecular mediators necessary for
Th cell differentiation are well studied, the mechanisms of how
these molecular mediators are regulated remains incompletely
understood.
Recent studies demonstrated that the kinase mTOR (known
as mammalian target of rapamycin) integrates environmental
cues provided by nutrients, cytokines, and costimulatory sig-
nals present in the immune microenvironment and helps to
promote Th cell differentiation (5–7). mTOR is a highly con-
served serine/threonine kinase of the PI3K family that exists
as a part of two complexes, mTORC1 and mTORC2. The
mTORC1 complex is characterized by the scaffold protein
Raptor and is activated by the small GTPase Rheb (8). Rapa-
mycin, a macrolide antibiotic and immunosuppressive agent,
inhibits mTORC1. We, and others (6, 9, 10), have recently
shown that mTORC1 and mTORC2 have differential contri-
butions to T helper differentiation. For example, in the absence
of Rheb and hence low mTORC1 activity, CD4+ T cells fail to
differentiate into Th1 and Th17 subsets; however, they are
capable of differentiating into Th2 cells. Furthermore, inhib-
iting mTORC1 with rapamycin also causes a defect in Th1
differentiation.
The transcription factor T-bet plays a critical role in Th1 dif-
ferentiation (3). One mechanism by which T-bet controls the ex-
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pression of its target genes is by recruiting cellular machinery that
conveys permissive and removes prohibitive epigenetic modifi-
cations, leading to gene transcription (11). Specifically, T-bet in-
teracts with a histone demethylase complex Jmjd3 that removes
repressive methylation H3K27 and histone methyltransferase
complex Set7/9 that adds permissive H3K4Me2 methylation.
T-bet promotes transcription of the essential Th1 genes such as
IFN-g, TNF-a, and CXCR3 and represses transcription of the Th2
and Th17 lineage-determining transcription factors GATA3 and
RORgt (4, 12). Although our laboratory has previously demon-
strated that mTORC1 is pivotal for Th1 differentiation (6), a
link between mTORC1 signaling and T-bet activity has yet to
be defined.
T-bet has been shown to undergo several types of posttransla-
tional modifications including phosphorylation and ubiquitination
(13, 14). T-bet phosphorylations at residues T302 and S508 are
involved in suppression of IL-2 production (14, 15); Y219/Y265/
Y304 triple phosphorylation by c-Abl tyrosine kinase regulates
T-bet’s ability to bind to DNA of its target genes and promotes
gene expression (16). Y304 is crucial for T-bet’s interaction with
RUNX1 transcription factor and inhibition of Th17 differentiation
(17). In light of the importance of these phosphorylation events on
the regulation of T-bet function (13–17), we hypothesized that
mTORC1 may also control T-bet’s activity via regulation of T-bet
phosphorylation.
To test this hypothesis, we developed a targeted mass spec-
trometry method that allows fast, reliable, and accurate phos-
phorylated peptide detection and quantitation. Most current
proteomic methods for discovery of novel phosphorylations in-
clude an enrichment step for phosphorylated peptides and sub-
sequent global proteomic analysis (18). Liquid chromatography
multiple reaction monitoring mass spectrometry (LC-MRM-MS)
can reproducibly detect low quantities of phosphorylated pep-
tides from complex biological samples without additional en-
richment due to the capability of specifically selecting only the
peptide of interest among a complex matrix (19, 20). We de-
veloped an LC-MRM-MS workflow to investigate whether
mTORC1 controls T-bet through phosphorylation. We discov-
ered five novel T-bet phosphorylations and established that four
of these novel phosphorylations are mTORC1 dependent. Three
of the mTORC1-dependent phosphorylations influence T-bet’s
ability to induce IFN-g production in EL4 and T-bet knockout
(KO) CD4+ T cells. Furthermore, simultaneous mutation of three
mTORC1-dependent phosphorylation sites impaired T-bet’s
ability to recruit chromatin-remodeling complexes to Ifng pro-
moter, as shown by a reduction in the permissive H3K4Me2




All reagents and chemicals were purchased from Sigma Aldrich unless
noted otherwise. Rapigest detergent was purchased from Waters. Anti-GFP
Alexa 488 Ab was purchased from Santa Cruz and mouse anti–IFN-g APC
Ab was purchased from eBioscience. IFN-g ELISA kit was purchased
from R&D Systems.
Mice
Rhebfl/fl mice were obtained from Dr. P. Worley (The Johns Hopkins
University, Baltimore) and were crossed with CD4Cre mice obtained
from the Jackson Laboratory to obtain Rhebfl/fl CD4Cre mice with T cell–
specific deletion of Rheb (21). Wild-type (WT) C57/BL6 mice were
obtained from the Jackson Laboratory and were bred and maintained
at Johns Hopkins University animal facility. All animal protocols were
approved by the Johns Hopkins Institutional Animal Care and Use
Committee.
T cell activation and in vitro Th1 differentiation
CD4+ T cells were purified from spleens and lymph nodes of WT C57/BL6
and CD4Cre Rhebfl/fl mice using Miltenyi CD4+ T cell negative selection
purification kit. Purified CD4+ T cells (87–95% purity) were plated into
six-well plates coated with 3 mg/ml of anti-CD3 Ab at 2–5 3 106 cells per
well. T cell cultures were supplemented with 2 mg/ml soluble anti-CD28,
50 ng/ml IFN-g, 10 ng/ml IL-12, and 1 mg/ml anti–IL-4 Ab. Some of the
WT T cell cultures were supplemented with 500 nM rapamycin. These
T cells were then cultured either 24 or 48 h in the 6% CO2, 37˚C tissue
culture incubator. CD4+ T cells were harvested and the cell pellets were
snap frozen in liquid nitrogen and stored at 280˚C until LC-MRM-MS
analysis.
Sample preparation for mass spectrometry analysis
T cell samples were prepared using a previously described Rapigest
mass spectrometry protocol (22) with several modifications. Frozen
pellets were thawed on ice and lysed with 0.15% Rapigest (Waters)
in 100 mM NH4HCO3 (pH 8.4) supplemented with phosphatase in-
hibitors 10 mM Na4O7P2, 50 mM NaF, and 1 mM Na3VO4. Protein
FIGURE 1. Proteomic workflow for discovery and validation of novel
T-bet phosphorylation sites. (A), Mouse T-bet protein sequence was used as
an input for phosphorylation site prediction analysis using NetPhos pro-
gram. T-bet phosphorylations with the highest predicted scores were
chosen for LC-MRM-MS method development. (B) Phosphorylation sites
and their NetPhos scores that were chosen for preliminary MRM method
development.
FIGURE 2. Six phosphorylation sites were detected and validated
using MRM-MS. (A) Schematic of T-bet protein with T-box DNA-
binding domain shown as a gray rectangle in the middle. The numbers
in gray circles show the location of the six different phosphorylations
on the T-bet sequence. (B) List of the six phosphorylations detected
using MRM-MS and their corresponding tryptic peptides. Five of these
phosphorylations are novel and one has been previously published
(15).
minute 2 to 26, followed by an increase to 98% B from minute 26 to 27,
then maintained at 5% B from minute 27 to 30. Mobile phase A was 0.1%
formic acid in LC-MS grade H2O. Mobile phase B was 0.1% formic acid
in 90% acetonitrile. Column compartment was heated to 40˚C.
Site-directed mutagenesis of T-bet
Mouse WT T-bet in the MigR1 retroviral vector has been previously de-
scribed (25, 26). All of the mutants (shown in Fig. 5A) were made using
the QuikChange Lightning site-directed mutagenesis kit (Stratagene)
according to the manufacturer’s protocol. Mutagenesis was verified by
sequencing. Triple mutant creation and sequencing verification was con-
ducted by GenScript.
EL4 transfection
EL4 cells were maintained in RPMI with 10% FBS and antibiotics,
subsequently noted as EL4 media. EL4 transfections were performed by
electroporating 5 3 106 cells with 15 mg of mutant or WT T-bet con-
taining MigR1 vector. Transfection efficiency was monitored by per-
centage GFP expression using flow cytometry. For IFN-g production
measurements percentage of GFP+ EL4 cells was measured by flow
cytometry and 0.8–1 3 105 GFP+ cells were plated per well of a 24-well
plate in 800 mL of EL4 media. Cells were activated with PMA/
ionomycin, and 24 h later supernatants were collected and IFN-g
amount was measured by ELISA. For intracellular cytokine staining
(ICS) transfected EL4 cells were plated in round-bottom 96-well plates
and stimulated with PMA/ionomycin in the presence of GolgiPlug (BD
Biosciences) overnight. Stimulated cells were harvested and fixed using
BD Fix/Perm reagent and later stained for IFN-g in BD Perm/Wash
solution.
FIGURE 3. LC-MRM-MS traces of T-bet
peptides that contain phosphorylations regulated
by mTORC1. Different color traces represent
different fragments of the same peptide. The
fragments are denoted at the top of each LC-
MRM-MS trace. (A) S52 phosphorylation site,
peptide AGSSLGTPYSGGALVPAAPGR, (B) Y76
phosphorylation site, peptide FLGSFAYPPR, (C)
S224 phosphorylation site, peptide LYVHPDSPNT-
GAHWMR. Data are representative of five individ-
ual experiments.
concentration of resulting lysates was measured by Bradford assay and 
proteins were digested overnight with sequencing grade modified 
trypsin (Promega) at 1:50 trypsin:protein ratio. Digested samples were 
acidified to pH 2.5–3 by 10% trifluoroacetic acid then incubated at 37˚C 
for 1 h. Next the samples were snap frozen in liquid nitrogen and 
allowed to thaw at room temperature to promote Rapigest precipita-
tion. Then samples were microcentrifuged at 15,000 rpm for 10 min to 
pellet precipitated Rapigest. Supernatants containing tryptic peptides 
were removed and their pH was brought to 7.5–8 using 10% ammo-
nium hydroxide. Peptide concentration was measured using OD280 on 
a Nanodrop spectrophotometer. Then peptides were desalted using 
Pierce C18 spin columns (Thermo Fisher Scientific) according to the 
manufacturer’s protocol. Desalted peptides were lyophilized and stored 
at 220˚C until LC-MRM-MS analysis.
LC-MRM-MS
A list of predicted tryptic peptides containing phosphorylation sites of 
interest was generated using open source Skyline (23) software (McCoss 
Laboratory, University of Washington). Peptides and their transitions were 
imported into AB Sciex Analyst software to generate methods for AB 
Sciex 5500 triple quadrupole mass spectrometer. For every peptide, 4–5 
transitions (fragments) of the highest signal-to-noise ratio were chosen for 
quantitation study.
Ninety micrograms of peptides were loaded on to the column and an-
alyzed on AB Sciex 5500 triple quadrupole mass spectrometer interfaced 
with Shimadzu UFLC (an ultra flow liquid chromatographer). Peptides were 
separated on a Waters C18 Acquity BEH 1.7 mm, 1.0 3 50 mm2 column 
using the following 30 min gradient (24) of mobile phases A and B: 5%
mobile phase B for 2 min, then mobile phase B was increased to 60% from
Retroviral transduction of CD4+ T cells
MigR1 plasmids encoding an empty vector (EV), WT T-bet, or T-bet
mutants were transiently transfected into the 293 Phoenix Eco (27)
packaging cell line (obtained from American Type Culture Collection)
using Lipofectamine 2000. Supernatants were collected at 48 and 72 h,
pooled, and stored at 4˚C until use. CD4+ T cells were isolated from
spleens and lymph nodes of T-bet KO mice (28). T cells were activated
with 3 mg/ml plate-bound anti-CD3, 2 mg/ml soluble anti-CD28 Ab, and 1
ng/ml IL-2 for 48 h. Then activated T cells were harvested, resuspended in
fresh T cell media, retrovirus-containing supernatant, and transferred into
retronectin-coated 24-well plates. CD4+ T cells were spinfected in 24-well
plates for 2 h at 2500 rpm then resuspended in fresh T cell media with IL-2
(1 ng/ml), IL-12 (10 ng/ml), and anti–IL-4 Ab (1 mg/ml). Transduced
T cells were harvested after 48 h and assayed for IFN-g production by
ELISA and T-bet expression by flow cytometry.
Chromatin immunoprecipitation
A total of 3.53 106 cells expressing vectors containing WT, EV, and triple
mutant T-bet were resuspended in media at 107/ml, crosslinked with
formaldehyde (1% final concentration), washed, and lysed using the
Magna ChIP A/G Chromatin Immunoprecipitation Kit (EMD Millipore,
Billerica, MA) according to the manufacturer’s instructions. Nuclei were
pelleted and subjected to sonication. The optimized condition to shear the
chromatin was two cycles (5 min each) of 30 s sonication followed by 30 s
of rest for a total of 10 min using Bioruptor 300 (Diagenode, Denville, NJ).
For chromatin immunoprecipitation (ChIP), 50 ml chromatin aliquot was
incubated either with 10 mg of rabbit anti-dimethyl-histone H3K4Me2
(EMD Millipore) or 2 mg of normal rabbit IgG Ab (Santa Cruz Biotech-
nology, Santa Cruz). ChIP-grade protein A/G magnetic beads (20 ml) were
added to each and were incubated on a rotator overnight at 4˚C. ChIP
samples were washed following the Magna ChIP protocol. Protein/DNA
complexes were eluted, crosslinks reversed, and DNA was purified by
phenol/chloroform extraction and precipitation. Quantitative PCR was
performed using SYBR Green Master Mix (Applied Biosystems, War-
rington, U.K.). For DNA quantification, a standard curve was generated by
serial dilution of purified mouse genomic DNA (Promega, Madison, WI).
All ChIP samples were normalized to 2% input.
Luciferase assay
Plasmids including a pGL3 luciferase reporter controlled by the SOCS3
promoter and an expression vector encoding murine Bcl-6 were generously
provided by Amy Weinmann (University of Alabama at Birmingham) (29).
EL4 cells were transfected by electroporation as noted above using 10 mg
of MIGR1 T-bet expression vector with or without 10 mg of Bcl-6 ex-
pression vector and 3 mg of pGL3 SOCS3 reporter, 3 mg of pRLtk vector
encoding Renilla luciferase (Promega), and 1 mg of pMAX GFP (Lonza,
Basel, Switzerland). Total plasmid DNA per transfection was normalized
by MIGR1 plasmid without an expression insert. Cells were harvested 18–
24 h posttransfection and cultured with PMA and ionomycin for 6 h before
measuring firefly and Renilla luciferase activities using the Dual Glo Lu-
ciferase kit (Promega). Firefly luciferase activity was normalized to
Renilla luciferase activity and is presented as fold induction compared
with EV control.
Results
Development of a workflow for novel phosphorylation site
discovery
To discover novel T-bet phosphorylations and test our hypothesis
that mTORC1 controls T-bet function through phosphorylation, we
developed a hypothesis-driven targeted mass spectrometry work-
FIGURE 4. Three of the novel T-bet phosphorylations are mTORC1 dependent. (A) WT C57/BL6 (WT) or Rhebfl/fl CD4Cre (Rheb KO) CD4+ T cells
were purified from spleens and lymph nodes of 6–12-wk-old mice and activated with plate-bound anti-CD3 and soluble anti-CD28 for 24 h in Th1 po-
larizing culture conditions. Activated T cells were harvested, lysed with Rapigest, trypsin digested, and analyzed by LC-MRM-MS. Area under the curve
(AUC) on the y-axis is the measure of phosphorylated peptide abundance. Data are from one of two experiments with T cells from individual mice. (B)
CD4+ T cells were purified from spleens and lymph nodes of WT mice and activated for 48 h as in (A) in the presence or absence of 500 nM rapamycin (WT
or WT rapamycin), prepared and analyzed as in (A). Data are from one of three experiments with T cells from individual mice. (C) Schematic of T-bet with
phosphorylations shown as circles with numbers. Gray circles are the phosphorylation sites. White circles show phosphorylations that are mTORC1 de-
pendent. Data are from one of five experiments with T cells from individual mice.
containing these phosphorylations were chosen for further studies
(Fig. 2). Most of these sites (S52, T55, Y76, and Y117) are located
in the N terminus of T-bet (Fig. 2A). Interestingly, Y76 phos-
phorylation has been computationally predicted as a possible site
of c-Abl phosphorylation, but was not confirmed experimentally
(31). We were able to confirm that Y76 phosphorylation takes
place using MRM-MS. One of the phosphorylation sites, S224, is
located within the T-box DNA-binding domain and S508 is lo-
cated in the C-terminal region of T-bet. Two additional phos-
phorylation sites, Y76 and Y117, are located in the domain of
T-bet that is responsible for T-bet’s interaction, with histone de-
methylase complex Jmjd3 that removes repressive methylation
H3K27 and histone methyltransferase complex Set7/9 that adds
permissive H3K4Me2 methylation (32–34). Therefore, by com-
bining the phosphorylation prediction tool and targeted mass
spectrometry workflow, we were able to discover novel T-bet
phosphorylation sites.
Four out of five of the novel phosphorylations are reduced in
the absence of mTORC1 activity
We hypothesized that mTORC1 signaling might control Th1 dif-
ferentiation in part by regulating T-bet function through phos-
phorylation. To test this hypothesis, we conducted LC-MRM-MS
analysis on Rheb-deficient CD4+ T cells, as well as WT CD4+
FIGURE 5. Single phosphorylation site T-bet mutants are not deficient in their ability to induce IFN-g. (A) Six single phosphorylation site mutants. All of
the phosphorylation sites were mutated to alanines. (B) EL4 cells were transfected with WT, EV, or different mutants. At 24 h posttransfection equal
numbers of GFP+ cells were plated and activated with PMA/ionomycin overnight. Supernatants were analyzed for IFN-g by ELISA. Error bars are SEM.
(C) EL4 cells transfected as in (B) and stimulated with PMA/ionomycin overnight in the presence of GolgiPlug protein transport inhibitor. Data are from
one of three experiments.
flow (Fig. 1A). Because MRM requires a priori knowledge of 
peptides and phosphorylation sites within the protein of interest, 
we used the NetPhos phosphorylation prediction algorithm (30) 
to identify target peptides with predicted phosphorylation sites. 
We selected eight peptides containing a total of 10 potential 
phosphorylation sites for a preliminary MRM screen (Fig. 1B). 
Because NetPhos cannot always accurately predict true phos-
phorylation sites a few phosphorylation sites with low NetPhos 
prediction scores were included in the preliminary screen. One of 
these phosphorylation sites (S508) was previously published (15) 
and was included to validate method development. To validate T-
bet peptide identifications all six of the phosphorylated peptides 
and two of their unphosphorylated counterparts detected by MRM 
were validated by comparing the elution time and fragmentation 
pattern of peptides detected in T cell samples to elution time and 
fragmentation pattern of corresponding synthetic phosphorylated 
and unphosphorylated peptides (data not shown).
Identification of five novel T-bet phosphorylation sites
Using the workflow that combined NetPhos phosphorylation 
prediction together with LC-MRM-MS we were able to detect 6 out 
of the 10 phosphorylation sites examined. These six phosphory-
lation sites, including S508, were consistently detected by MRM in 
T cells from WT C57/BL6 cultured in Th1 conditions and peptides
T cells treated with rapamycin. MRM-MS analysis revealed that
S52, Y76, S224, and S508 (Fig. 3) phosphorylations are consis-
tently reduced when mTORC1 activity is abrogated (Figs. 3, 4).
Fig. 3 shows LC-MRM-MS traces for peptides containing S52,
Y76, and S224 phosphorylations. The abundance of these phos-
phorylations, as measured by the area under the curve for all
fragments of a particular peptide, was consistently decreased
(Fig. 4A, 4B). The abundance of the corresponding unphos-
phorylated peptides was similar for WT, Rheb KO, and WT
treated with rapamycin samples (data not shown).
Mutating single phosphorylation sites does not affect T-bet’s
ability to induce IFN-g expression
Published data (13, 14, 16) suggested that within T-bet, S52, Y76,
and S224 phosphorylation sites could be important for T-bet’s
ability to induce IFN-g expression by influencing its ability to
bind DNA and/or interact with chromatin remodeling complexes.
A distinct phosphorylation site, S508, has been previously dem-
onstrated to be important for suppression of IL-2 production by
T-bet (15).
To test the function of the six phosphorylation sites detected by
MRM-MS, we created alanine substitution mutants for each in-
dividually (Fig. 5A). The best characterized function of T-bet is
induction of IFN-g expression. This can be modeled by transient
overexpression of T-bet in the EL4 lymphoma cell line, which
does not express T-bet or IFN-g (3). T-bet expression in EL4 cells
is both necessary and sufficient to induce IFN-g, and such func-
tional analyses in EL4 cells have correlated strongly with T-bet
function in primary CD4+ T cells (29, 33–35). We transfected EL4
cells with either WT T-bet or T-bet mutants and measured IFN-g
production by ICS and ELISA. All of the T-bet single site mutants
were able to induce IFN-g expression (Fig. 5B, 5C) as shown by
ELISA and ICS. The level of IFN-g induced by mutants was either
similar or higher in magnitude as compared with the level of
IFN-g induced by WT T-bet. Therefore, mutating individual
phosphorylation sites is not sufficient to reduce T-bet’s ability to
induce IFN-g expression.
Mutating three of the mTORC1-dependent phosphorylations
reduces T-bet’s ability to induce IFN-g expression in EL4 and
T-bet KO CD4+ T cells
Because S52, Y76, and S224 phosphorylations are mTORC1 de-
pendent and are in the domains of T-bet that are important for
T-bet’s ability to induce its target gene expression (32–34), we
hypothesized that mutating all three of these phosphorylations
could impact T-bet’s ability to promote IFN-g expression.
Therefore, we created a triple mutant T-bet in which each of the
S52, Y76, and S224 phosphorylations were all simultaneously
FIGURE 6. Triple phosphorylation site T-bet mutant has a significantly reduced ability to induce IFN-g in EL4. (A) EL4 cells were transfected with WT,
EV, S52A single phosphorylation site mutant, or triple phosphorylation site mutant. At 24 h posttransfection equal numbers of GFP+ cells were plated and
activated with PMA/ionomycin overnight. Supernatants were analyzed for IFN-g by ELISA. Error bars are SEM, **p , 0.05 by one-way ANOVA with
Bonferroni multiple comparison test. (B) EL4 transfected as in (A) were fixed, permeabilized, and stained with anti-GFP and anti–T-bet Abs. (C) Samples
from (B) gated on GFP+ cells and T-bet levels are shown as histograms. Data are representative of four experiments.
deficient in their ability to secrete cytokines, because even though
they do not secrete IFN-g they secrete TNF-a at levels that are
similar to WT CD4+ T cells (Supplemental Fig. 3). T-bet KO
CD4+ T cells were transduced with retroviruses containing WT,
triple mutant, EV, and S224A single phosphorylation site mutant
constructs (Fig. 7). Similar to the EL4 experiments, we observed
that the triple mutant has a significantly reduced ability to induce
IFN-g expression in T-bet KO CD4+ T cells as compared with WT
T-bet (Fig. 7A).
Triple mutant T-bet has an impaired ability to promote
chromatin remodeling
To understand why the triple mutant T-bet has a diminished ability
to promote IFN-g expression we investigated the triple mutant’s
ability to promote addition of the permissive chromatin mark
H3K4Me2. The presence of this chromatin mark at Ifng promoter
has been demonstrated to be exquisitely T-bet dependent in EL4
and primary T cells (32). Furthermore, EL4 cells have been suc-
cessfully used to study chromatin remodeling induced by T-bet
and these findings directly translated into chromatin remodeling
FIGURE 7. Triple phosphorylation site T-bet mutant has a significantly reduced ability to induce IFN-g in T-bet–deficient primary CD4+ T cells. (A)
CD4+ T cells were purified from spleens and lymph nodes of T-bet–deficient (T-bet KO) mice and transduced with WT, EV, S224A single phosphorylation
site mutant, or triple mutant construct containing retroviruses. At 48 h posttransduction equal numbers of GFP+ cells were plated and activated with 1 mg/ml
plate-bound anti-CD3 and 2 mg/ml soluble anti-CD28 overnight. Supernatants were analyzed for IFN-g by ELISA. Error bars are SEM, **p, 0.05 by one-
way ANOVA with Bonferroni multiple comparison test. (B) T-bet KO CD4+ T cells transduced with the constructs indicated in (A) were fixed, per-
meabilized, and stained with anti-GFP and anti–T-bet Abs. (C) Samples from (B) gated on GFP+ cells and T-bet levels are shown as histograms. Data are
from one of two experiments with T cells from four individual mice.
mutated to alanine. The resulting triple mutant was transfected 
into EL4 cells and its ability to induce IFN-g was compared with 
WT T-bet. Triple mutant T-bet has a significantly reduced ability 
to induce IFN-g expression as compared with WT T-bet, as shown 
by either transient transfection via electroporation (Fig. 6A) or 
stable retroviral transduction (Supplemental Fig. 1A) of WT or 
triple mutant T-bet in EL4 cells. It should be noted that trans-
fection efficiency and T-bet protein levels by Western blot and ICS 
were similar for WT and triple mutant T-bet over the course of 
multiple experiments (Fig. 6B, 6C, Supplemental Fig. 1). This is 
readily seen in the EL4 cells stably transfected with T-bet or the 
T-bet mutants (Supplemental Fig. 1). Having employed the EL4 
cell line to identify the functional importance of the mTORC1-
dependent phosphorylation sites, we next wanted to test the mu-
tant T-bet constructs in primary CD4+ T cells. To study the ability 
of the triple mutant to induce IFN-g production in primary T cells 
we used CD4+ T cells from T-bet KO mice. Of note, T-bet KO 
CD4+ T cells have similar levels of Rheb protein and mTORC1 
activity when compared with WT CD4+ T cells (Supplemental 
Fig. 2). Furthermore, T-bet KO CD4+ T cells are not globally
induced by T-bet in primary CD4+ T cells (29, 33–35). ChIP using
H3K4Me2 Ab demonstrated that the triple mutant T-bet has a
significantly reduced ability to promote addition of the permissive
histone methylation mark at Ifng promoter region (Fig. 8A). Al-
ternatively, the Ifng promoter-driven luciferase reporter assay,
which is not regulated at the epigenetic level, can be used as a
measure of T-bet’s ability to bind DNA at a target promoter in-
dependently of chromatin-remodeling events (33). By this mea-
sure, the triple mutant T-bet’s ability to bind DNA at the Ifng
promoter region was intact (Fig. 8B). It has been demonstrated
that T-bet interacts with the Bcl-6 transcription factor. The T-bet/
Bcl-6 complex attenuates the expression of T-bet target genes
instead of upregulating them (29). Bcl-6 binding to T-bet has
shown to take place at the C terminus of T-bet. One of the
phosphorylations that we investigated is S508 phosphorylation site
and it is located with the C-terminal region of T-bet that has been
shown to interact with Bcl-6 (29, 35). We investigated whether
novel T-bet phosphorylations we identified impact T-bet’s ability
to interact with Bcl-6 by cotransfecting T-bet and Bcl-6 into EL4
and monitoring induction of SOCS3 transcription via SOCS3 lu-
ciferase promoter-reporter assay. Neither the single phosphoryla-
tion mutants nor the triple mutant impacted T-bet’s ability to
interact with Bcl-6 as shown by the same degree of SOCS3 re-
porter inhibition for EL4 cotransfected with either WT or mutant
T-bet and Bcl-6 (Fig. 8C). Of note, T-bet and Bcl-6 protein levels
were similar between the different conditions used for the SOCS3
reporter assay (Supplemental Fig. 4). Together these results
demonstrate that triple mutant T-bet can bind DNA and interact
with Bcl-6 but has an impaired ability to induce IFN-g expression
due to reduction in its capacity to promote an appropriate per-
missive epigenetic environment.
Discussion
In the current study we have identified five novel T-bet phos-
phorylation sites and demonstrate that four of these phosphory-
FIGURE 8. Triple mutant T-bet has a reduced ability to promote addition of permissive chromatin-remodeling mark H3K4Me2 but can still bind to the
Ifng and SOCS3 promoters. (A) EL4 cells were transiently transfected with EV, WT T-bet, or T-bet triple mutant, and chromatin was fixed after 72 h and
sonicated for ChIP. Graph depicts fraction of input DNA precipitated by anti-H3K4Me2–specific Ab from each sample, mean6 SD, n = 3 replicates. **p,
0.05 by one-way ANOVA with Bonferroni multiple comparison test. Control rabbit IgG precipitated a negligible amount of input and is not shown. The
experiment was performed three times with similar results. (B) EL4 cells were cotransfected with the pGL3 Ifng promoter-reporter construct, pRLtk Renilla
control, and with WT T-bet, triple mutant T-bet, or EV. After PMA/ionomycin stimulation, firefly luciferase activity was normalized to the activity of
cotransfected Renilla control. Graph depicts relative luminescence units (RLU). Data are from one of two experiments. Error bars are SD, **p , 0.05 by
one-way ANOVAwith Bonferroni multiple comparison test. (C) EL4 were cotransfected with the SOCS3 luciferase promoter-reporter construct and EVor
T-bet constructs in the absence (open bars) or the presence (gray bars) of Bcl-6. After PMA/ionomycin stimulation, firefly luciferase activity was nor-
malized to cotransfected Renilla luciferase activity and is depicted as fold induction compared with EV. Error bars depict SD, and data are representative of
four independent experiments.
T-bet–dependent SOCS3 promoter transcription.
Previously three other T-bet phosphorylation sites within the
T-box region (Y219/Y265/Y304) have been demonstrated to be
crucial for T-bet’s ability to bind DNA proximal to its target
genes (16). T-bet promotes the expression of its target genes via
two mechanisms. The first mechanism is through T-bet directly
binding to the consensus sequence in its target gene’s promoter
or enhancer region and recruiting transcription machinery, and
the second is through recruiting chromatin-remodeling com-
plexes to its target gene promoter and facilitating the addition of
permissive and removal of prohibitive chromatin-remodeling
marks (11, 32–34, 36). Studies from the Weinmann laboratory
(32–34) have demonstrated that T-bet regions that are respon-
sible for recruitment of chromatin-remodeling complexes are
predominantly located on the N terminus of T-bet and overlap
with T-box DNA-binding domain. Therefore, we hypothesized
that S224, S52, and Y76 mTORC1-dependent phosphorylations
discovered in this study could be important for recruiting
chromatin-remodeling complexes. Our data supports this hy-
pothesis by demonstrating that a triple mutant T-bet binds to and
activates an Ifng promoter-reporter construct but has a reduced
ability to promote the addition of the H3K4Me2 permissive
chromatin mark to the endogenous Ifng promoter region within
chromatin.
Y219/Y265/Y304 phosphorylations that regulate T-bet’s DNA
binding and ability to promote Th1 differentiation are imparted
onto T-bet by c-Abl tyrosine kinase (16). Among the novel
mTORC1-dependent phosphorylation sites discovered in this
study, there are both serine (S52, S224) and tyrosine (Y76)
phosphorylation. Therefore, these phosphorylations may be
imparted onto T-bet by two distinct kinases, one with serine/
threonine specificity and another with tyrosine specificity, or a
dual-specificity kinase. Such findings suggest that at least some of
the phosphorylation sites we identified are not direct substrates of
mTORC1, despite the regulation of their phosphorylation state by
mTORC1 activity. Although identification of the kinases that di-
rectly phosphorylate the T-bet residues that we identified is be-
yond the scope of this work, preliminary immunoprecipitation
studies have identified interactions between mTORC1 and several
dual-specificity protein kinases. The capacity of these kinases
to phosphorylate T-bet on the sites we identified remains under
investigation.
Interestingly, four out of five novel phosphorylation sites in
mouse T-bet protein discovered in this study are present in human
T-bet. Previous studies from our laboratory (37) have demonstrated
that mTOR regulates human CD4+ T cell effector differentiation.
Thus, we predict that mTORC1 regulates T-bet function via
phosphorylation not only in mouse CD4+ T cells but in human
CD4+ T cells as well.
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